Vivos Therapeutics (VVOS) Return on Capital Employed (2021 - 2026)
Vivos Therapeutics (VVOS) posted quarterly Return on Capital Employed of 315.56% for Q1 2026, down 18384.0% year-over-year from N/an in Q1 2025, and down 16.11% quarter-over-quarter from 271.77% in Q4 2025.
Vivos Therapeutics (VVOS) Return on Capital Employed (2021 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported Return on Capital Employed for 6 consecutive years, with 315.56% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 18384.0% year-over-year to 315.56%; the TTM figure through Mar 2026 stood at 315.56% (down 18384.0% YoY), while the FY2025 annual figure was 928.76%, down 78963.0% from the prior year.
- Return on Capital Employed retreated to 315.56% in Q1 2026 per VVOS's latest filing, from 271.77% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 88.7% in Q3 2025 and bottomed at 534.7% in Q4 2023.
- Historically, Return on Capital Employed has averaged 238.5% across 5 years, with a median of 187.94% in 2024.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 26356 bps — and 2024, when it surged 42663 bps.
- Vivos Therapeutics' Return on Capital Employed stood at 271.15% in 2022, then tumbled by 97 bps to 534.7% in 2023, then soared by 80 bps to 108.07% in 2024, then plunged by 151 bps to 271.77% in 2025, then dropped by 16 bps to 315.56% in 2026.
- Business Quant data shows VVOS's Return on Capital Employed at 315.56% in Q1 2026, 271.77% in Q4 2025, and 88.7% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 7.98% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 13.69% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 10.83% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 11.99% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 27.21% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 9.47% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 12.84% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 12.08% |
| 10 | Vivos Therapeutics | 5.18 Mn | 3.38 Mn | 2.95 Mn | -536.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -315.56% |
| Dec 31, 2025 | -271.77% |
| Sep 30, 2025 | -88.70% |
| Jun 30, 2025 | -116.37% |
| Mar 31, 2025 | -131.73% |
| Dec 31, 2024 | -108.07% |
| Sep 30, 2024 | -119.40% |
| Jun 30, 2024 | -187.94% |
| Mar 31, 2024 | -502.82% |
| Dec 31, 2023 | -534.70% |
| Sep 30, 2023 | -395.09% |
| Jun 30, 2023 | -300.55% |
| Mar 31, 2023 | -315.25% |
| Dec 31, 2022 | -271.15% |
| Sep 30, 2022 | -171.30% |
| Jun 30, 2022 | -130.81% |
| Mar 31, 2022 | -93.22% |
| Dec 31, 2021 | -68.28% |
| Sep 30, 2021 | -54.29% |
| Jun 30, 2021 | -62.78% |